Lexicon Genetics Awarded Additional Grant for Study of Spinal Muscular Atrophy
Lexicon Genetics Incorporated announced that its research program to identify targets that may be important in the development of drugs to prevent or treat spinal muscular atrophy (SMA) has been extended for an additional year by the United States Army Medical Research & Materiel Command (USAMRMC). SMA is a neurodegenerative disorder and a genetic cause of death in early childhood.
Lexicon will receive $2.5 million in funding for the one-year extended term of the grant. The research program was initiated under a $2.0 million award to Lexicon. Lexicon has an agreement with the SMA Foundation for the potential development of drugs based on discoveries resulting from this program.
Spinal muscular atrophy is a genetic, motor-neuron disease characterized by the wasting of skeletal muscles. Caused by progressive degeneration of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy and premature death due to respiratory problems.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Investigational agent shows promise in reducing spread of prostate cancer
Combination drug targeting opioid system may help relieve treatment-resistant depression

Midlife obesity linked to heightened frailty risk in older age - Findings highlight importance of keeping trim throughout adulthood
MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to Develop Novel Antibody Therapies
